The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals gained 20.4%, fueled by its CF franchise and new therapies, Alyftrek and Journavx, with potential blockbuster status for the latter. Alphabet Inc. was the biggest laggard at ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, ...